Your session is about to expire
← Back to Search
TT-00420 for Breast Cancer
Study Summary
This trial is testing a new drug called TT-00420 for the treatment of triple negative breast cancer and other advanced solid tumors. The trial has two parts - one where they test different doses of the
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the trial currently accepting new participants?
"The information provided on clinicaltrials.gov indicates that patient recruitment for this specific trial is not currently ongoing. The trial was initially posted on January 8th, 2019 and last updated on October 25th, 2021. However, it's worth noting that there are presently 2,832 other active clinical trials actively seeking participants."
What level of risk does TT-00420 pose to individuals receiving treatment?
"Considering that this trial is in Phase 1, which implies limited available data on safety and efficacy, the estimated safety rating for TT-00420 by our team at Power is 1."
Is the age bracket of participants extended to individuals below 18 years old for this investigation?
"Prospective participants who are between the ages of 18 and 75 meet the eligibility criteria for this clinical trial. There is a separate pool of 71 trials specifically designed for patients under 18 years old, while another set of 2748 trials cater to individuals over the age of 65."
Share this study with friends
Copy Link
Messenger